While dry mouth can occur with many medications, health conditions, or dehydrationnot just GLP-1s
(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority
Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking
Yang Y, Cui X, Chen Y, Wang Y, Li X, Lin L, Zhang H (2014) Exendin-4, an analogue of glucagon-like peptide-1, attenuates hyperalgesia through serotonergic pathways in rats with neonatal colonic sensitivity
Further Reading: Spermidine for Weight Loss Resveratrol: Does resveratrol help with weight loss
Evolocumab is used to reduce the risk of major adverse cardiovascular events (MACE) (such as a stroke or heart attack) in adults at increased risk for these events, and to reduce low-density lipoprotein cholesterol (LDL-C) levels in adults and children over the age of 10 with certain types of high cholesterol in addition to diet or in combination with other LDL-C lowering treatments